Progentos is developing first-in-class compounds to induce endogenous oligodendrocyte progenitor cells to remyelinate axons in patients suffering from Multiple Sclerosis (MS) and other demyelinating diseases
Progentos is developing first-in-class compounds to induce endogenous oligodendrocyte progenitor cells to remyelinate axons in patients suffering from Multiple Sclerosis (MS) and other demyelinating diseases. The company focuses on regenerative medicine to improve the quality of life for patients with chronic neurological conditions.